IINNW
🚫 does not pay dividends

Company News

Inspira Technologies (IINN) Falls After-Hours — What's Going On?
Benzinga • Tanya Rawat • April 17, 2026

Inspira Technologies (NASDAQ: IINN) stock fell 5.96% in after-hours trading despite announcing a commercial deployment of its AME system at a U.S. defense customer site. The agreement includes ongoing supply of proprietary consumables and materials for recurring revenue, though financial terms and customer identity were not disclosed. The stock c...

Nano Dimension Announces the Sale of AME and Fabrica Product Lines
Benzinga • Na • April 6, 2026

Nano Dimension Ltd. announced the sale of its additively manufactured electronics (AME) and Fabrica product lines to Inspira Technologies OXY B.H.N. Ltd. for up to $12.5 million ($2.0 million upfront plus $10.5 million in deferred payments). The transaction is expected to reduce Nano's annualized cash burn by approximately $10 million and represe...

CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
Benzinga • Globe Newswire • January 5, 2026

Inspira Technologies Oxy (NASDAQ: IINN) announced a non-binding term sheet for acquiring an advanced liquid biopsy diagnostics business and receiving a $15 million strategic equity investment at a $180 million pre-money valuation. The acquisition includes an AI-powered platform for isolating and characterizing circulating tumor cells from blood s...

Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
Benzinga • Globe Newswire • January 5, 2026

Inspira Technologies Oxy has signed a non-binding term sheet to acquire an advanced liquid biopsy diagnostics business and receive a $15 million strategic equity investment at a $180 million pre-money valuation. The acquisition includes a proprietary platform for isolating and characterizing circulating tumor cells with AI-powered analysis, targe...

Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
Benzinga • Prnewswire • March 11, 2025

Inspira Technologies reported its full-year 2024 financial results, highlighting progress in its HYLA blood sensor and INSPIRA ART core technologies, as well as the deployment of its FDA-cleared INSPIRA ART100 system to leading hospitals.

Related Companies